Grp78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients

Annals of Oncology

Volumn 22, Issue 11, 2011, Pages 2431-2439

  Winder, T ^a   Bohanes, P ^a   Zhang, W ^a   Yang, D ^b   Power, D G ^c   Ning, Y ^a   Gerger, A ^a   Wilson, P M ^b   Tang, L H ^c   Shah, M ^c   Lee, A S ^b   Lenz, H J ^a,b  

^a Department of Internal Medicine Division of Medical Oncology Starling Loving Hall   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Department of Obstetrics Gynecology   (United States)

Author keywords

Colorectal cancer; Gastric cancer; GRP78; Outcome; Polymorphism

Indexed keywords

CISPLATIN; CYTOSINE; DNA; FLUOROURACIL; FOLINIC ACID; FORMALDEHYDE; GLUCOSE REGULATED PROTEIN 78; IRINOTECAN; OXALIPLATIN; PARAFFIN; THYMINE;

ADJUVANT THERAPY; ADULT; ARTICLE; BLOOD SAMPLING; CANCER CENTER; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; COHORT ANALYSIS; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; EMBEDDING; FEMALE; GASTRECTOMY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HAZARD RATIO; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; RECURRENCE RISK; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH ADENOCARCINOMA; UNITED STATES; UNIVARIATE ANALYSIS;

EID: 80155124379     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq771     Document Type: Article

References (37)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5): 277-300.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Gunderson LL, Jessup JM, Sargent DJ et al. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010; 28: 264-271.
4. D'Angelica M, Gonen M, Brennan MF et al. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004; 240: 808-816.
5. Goldberg RM, Fleming TR, Tangen CM et al. Surgery for recurrent colon cancer: strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med 1998; 129: 27-35.
6. Dong D, Ni M, Li J et al. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res 2008; 68: 498-505.
7. Gething MJ. Role and regulation of the ER chaperone BiP. Semin Cell Dev Biol 1999; 10: 465-472.
8. Lee AS. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci 2001; 26: 504-510.
9. Li J, Lee AS. Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 2006; 6: 45-54.
10. Ma Y, Hendershot LM. The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer 2004; 4: 966-977.
11. Gonzalez-Gronow M, Selim MA, Papalas J, Pizzo SV. GRP78: a multifunctional receptor on the cell surface. Antioxid Redox Signal 2009; 11: 2299-2306.
12. Zhang J, Jiang Y, Jia Z et al. Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin Exp Metastasis 2006; 23: 401-410.
13. Zheng HC, Takahashi H, Li XH et al. Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas. Hum Pathol 2008; 39: 1042-1049.
14. Xing X, Lai M, Wang Y et al. Overexpression of glucose-regulated protein 78 in colon cancer. Clin Chim Acta 2006; 364: 308-315.
15. Jamora C, Dennert G, Lee AS. Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/C10ME. Proc Natl Acad Sci U S A 1996; 93: 7690-7694.
16. Reddy RK, Mao C, Baumeister P et al. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem 2003; 278: 20915-20924.
17. Dong D, Ko B, Baumeister P et al. Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment. Cancer Res 2005; 65: 5785-5791.
18. Ermakova SP, Kang BS, Choi BY et al. (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res 2006; 66: 9260-9269.
19. Lee E, Nichols P, Groshen S et al. GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy. Int J Cancer 2010; 28: 726-731.
20. Lee E, Nichols P, Spicer D et al. GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res 2006; 66: 7849-7853.
21. Hsu WC, Wang HK, Lee LC et al. Promoter polymorphisms modulating HSPA5 expression may increase susceptibility to Taiwanese Alzheimer's disease. J Neural Transm 2008; 115: 1537-1543.
22. Kakiuchi C, Ishiwata M, Nanko S et al. Functional polymorphisms of HSPA5: possible association with bipolar disorder. Biochem Biophys Res Commun 2005; 336: 1136-1143.
23. Lee AS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 2007; 67: 3496-3499.
24. Daneshmand S, Quek ML, Lin E et al. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol 2007; 38: 1547-1552.
25. Zhang LJ, Chen S, Wu P et al. Inhibition of MEK blocks GRP78 up-regulation and enhances apoptosis induced by ER stress in gastric cancer cells. Cancer Lett 2009; 274: 40-46.
26. Arap MA, Lahdenranta J, Mintz PJ et al. Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 2004; 6: 275-284.
27. Wang M, Wey S, Zhang Y et al. Role of the unfolded protein response regulator GRP78/BiP in development, cancer, and neurological disorders. Antioxid Redox Signal 2009; 11: 2307-2316.
28. Zhang Y, Liu R, Ni M et al. Cell surface relocalization of the endoplasmic reticulum chaperone and unfolded protein response regulator GRP78/BiP. J Biol Chem 2010; 285: 15065-15075.
29. Misra UK, Sharma T, Pizzo SV. Ligation of cell surface-associated glucose-regulated protein 78 by receptor-recognized forms of alpha 2-macroglobulin: activation of p21-activated protein kinase-2-dependent signaling in murine peritoneal macrophages. J Immunol 2005; 175: 2525-2533.
30. Misra UK, Deedwania R, Pizzo SV. Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78. J Biol Chem 2006; 281: 13694-13707.
31. Kelber JA, Panopoulos AD, Shani G et al. Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways. Oncogene 2009; 28: 2324-2336.
32. Pyrko P, Schonthal AH, Hofman FM et al. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res 2007; 67: 9809-9816.
33. Virrey JJ, Dong D, Stiles C et al. Stress chaperone GRP78/BiP confers chemoresistance to tumor-associated endothelial cells. Mol Cancer Res 2008; 6: 1268-1275.
34. Baumeister P, Dong D, Fu Y, Lee AS. Transcriptional induction of GRP78/BiP by histone deacetylase inhibitors and resistance to histone deacetylase inhibitorinduced apoptosis. Mol Cancer Ther 2009 May 5 [Epub ahead of print].
35. Liu Y, Steiniger SC, Kim Y et al. Mechanistic studies of a peptidic GRP78 ligand for cancer cell-specific drug delivery. Mol Pharm 2007; 4: 435-447.
36. Passarella RJ, Spratt DE, van der Ende AE et al. Targeted nanoparticles that deliver a sustained, specific release of paclitaxel to irradiated tumors. Cancer Res 2010; 70: 4550-4559.
37. Fu Y, Wey S, Wang M et al. Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium. Proc Natl Acad Sci U S A 2008; 105: 19444-19449.